Loading stock data…
$2.05-0.05 (-2.38%)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. in the Healthcare sector is trading at $2.05 with a market capitalization of $420M. Wall Street consensus targets $2.40 (7 analysts), implying a +17.1% move over the next 12 months. The stock is currently 40% below its 52-week high of $3.44, remaining 28.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $39.01M↑ | $37.18M↓ | $44.65M↑ | $38.44M↓ | $39.77M |
| Gross Profit | $12.64M↓ | $12.84M↓ | $16.57M↑ | $15.90M↑ | $14.68M |
| Operating Income | -$44.61M↑ | -$54.15M↓ | -$41.20M↓ | -$38.88M↑ | -$44.85M |
| Net Income | -$44.74M↓ | -$8.28M↑ | -$40.37M↓ | -$38.00M↑ | -$41.93M |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technol...